RxDoctor Payments Data

Jennifer Tremmel, MD

Interventional Cardiology · Stanford, CANPI 1093733909

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $163,419 of the $233,347 with a category attached, or 70.0%. 11 manufacturers reported payments, led by Abbott at 50.0% of the total. Among interventional cardiology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$233,347in general payments, 2019–2025

Across 163 payments — averaging $1431.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$117K
  • Boston Scientific$59K
  • Terumo Medical Corporation$17K
  • Philips North America LLC$13K
  • Cordis US CORP.$12K
  • Shockwave Medical, Inc$11K
  • plus $4K from 5 others
$601,296in research payments, 2019–2025

Across 66 payments — averaging $9110.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Shockwave Medical, Inc$364K
  • Boston Scientific$213K
  • Medtronic$24K

What the payments were for

  • Consulting fees$163,41970%
  • Speaking & faculty fees$39,22517%
  • Travel & lodging$26,39111%
  • Food & beverage$4,3122%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott44$116,726
Boston Scientific75$59,011
Terumo Medical Corporation14$17,351
Philips North America LLC6$13,404
Cordis US CORP.9$11,539
Shockwave Medical, Inc9$10,964
Edwards Lifesciences2$3,750
Cathworks, Inc.1$261
Medtronic1$136
Abiomed1$119
Seigla Medical, Inc.1$86

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$233,347 in reported general payments places this provider in the 95th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$102,379
Medicare patients
403
Services billed
758

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab50$52,115
Nebivolol Hcl17$1,630
ClopidogrelClopidogrel Bisulfate77$1,149
Rosuvastatin Calcium80$1,148
Ezetimibe20$957
Nitroglycerin29$821
Atorvastatin Calcium85$747
Diltiazem 24hr Er (Cd)Diltiazem Hcl15$703
Valsartan16$683
Metoprolol Succinate50$458
Losartan Potassium23$328
Carvedilol19$310
Isosorbide Mononitrate ErIsosorbide Mononitrate14$254
Lisinopril18$236
Amlodipine Besylate34$220

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Stanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →